Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.33 |
| ▸ | MAT2A | P31153 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.30 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14107624 | 0.96 | IRAK4 (0.36) | MAPK8IRAK4 | |
| SCHEMBL13408587 | 0.90 | MAPK1 (0.36) | MAPK8IRAK4 | |
| SCHEMBL14107677 | 0.86 | MAPK1 (0.40) | MAPK8IRAK4 | |
| SCHEMBL3297113 | 0.85 | MAOB (0.34) | MAPK8IRAK4MAT2AMAOBHTR6 | |
| SCHEMBL3297110 | 0.85 | MAOB (0.34) | MAPK8IRAK4MAT2AMAOBHTR6 | |
| SCHEMBL13942083 | 0.85 | IRAK4 (0.36) | MAPK8IRAK4 | |
| SCHEMBL13409628 | 0.84 | MAPK8 (0.34) | MAPK8IRAK4MAOBHTR6 | |
| SCHEMBL13408627 | 0.82 | USP2 (0.34) | MAPK8 | |
| SCHEMBL3299220 | 0.80 | IRAK4 (0.36) | MAPK8IRAK4 | |
| SCHEMBL13409168 | 0.80 | MAPK1 (0.33) | IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | PYGL, PYGM, G6PC1 | MAPK8 2865/4885IRAK4 2516/4885MAT2A 1431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.